Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
2006 May 01
Journal Article
Authors:
Treanor, J.J.;
Schiff, G.M.;
Couch, R.B.;
Cate, T.R.;
Brady, R.C.;
Hay, M.;
Wolff, M.;
She, D.;
Cox, M.M.J.
Secondary:
J Infect Dis
Volume:
193
Pagination:
1223-8
Issue:
9
PMID:
16586358
DOI:
10.1086/503050
Keywords:
Adult; Aged; Aged, 80 and over; Antibodies, Viral; Baculoviridae; Dose-Response Relationship, Immunologic; Female; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza Vaccines; Male; Maximum Tolerated Dose; Middle Aged; Vaccines, Inactivated
Abstract:
BACKGROUND: Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine.METHODS: In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA.RESULTS: Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA.CONCLUSIONS: Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.
